Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pamiparib for germline BRCA mutation-associated recurrent advanced ovarian, fallopian tube or primary peritoneal cancer.

Drugs of today (Barcelona, Spain : 1998) - 1 Jun 2022

Skrzypczyk-Ostaszewicz Anna

Abstract excerpt

Epithelial ovarian cancers are gynecological malignancies with the poorest prognosis. Intensive research over the past few years has demonstrated ovarian cancer is a type of cancer in which new molecularly targeted drugs significantly affect patients' fate and prognosis. These drugs are poly [ADP-ribose] polymerase (PARP) inhibitors, which are used for maintenance treatment. These molecules continue to be...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Ovarian Epithelial
Share to Fallopian Tubes

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Fluorenes

Share to Germ Cells

Share to Ovarian Neoplasms

Share to Poly(ADP-ribose) Polymerase Inhibitors

Share to Prostatic Neoplasms

Share to Tumor Suppressor Proteins

Source

Identifiers

PMID: 35670707
DOI: 10.1358/dot.2022.58.6.3389001

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pamiparib for germline BRCA mutation-associated recurrent advanced ovarian, fallopian tube or primary peritoneal cancer.PMID 35670707Read ↗

Characteristics of Patients with Newly Diagnosed High-Grade Advanced Ovarian, Fallopian Tube and Primary Peritoneal Cancer in 2018–2023 and the Impact of Molecular Diagnostics on the Chemotherapy in Clinical PracticeSemantic proximity Read ↗

PARP Inhibitors in the Management of Ovarian Cancer: ASCO GuidelineSemantic proximity Read ↗

Rucaparib versus standard-of-care chemotherapy in patients with relapsed ovarian cancer and a deleterious BRCA1 or BRCA2 mutation (ARIEL4): an international, open-label, randomised, phase 3 trial.Semantic proximity Read ↗

A Pan-Canadian Consensus Statement on First-Line PARP Inhibitor Maintenance for Advanced, High-Grade Serous and Endometrioid Tubal, Ovarian, and Primary Peritoneal Cancers.Semantic proximity Read ↗

PARP Inhibitors in Ovarian CancerSemantic proximity Read ↗

Benefit from maintenance with PARP inhibitor in newly diagnosed ovarian cancer according to BRCA1/2 mutation type and site: a multicenter real-world studySemantic proximity Read ↗

A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation — An NRG Oncology/Gynecologic Oncology Group studySemantic proximity Read ↗

Rucaparib in ovarian cancer: extending the use of PARP inhibitors in the recurrent disease.Semantic proximity Read ↗

PARP inhibitors in ovarian cancer: An overview of the practice‐changing trialsSemantic proximity Read ↗

Olaparib and advanced ovarian cancer: Summary of the past and looking into the futureSemantic proximity Read ↗

Niraparib and Advanced Ovarian Cancer: A Beacon in the Non-BRCA Mutated SettingSemantic proximity Read ↗

Evaluation of Rucaparib and Companion Diagnostics in the PARP Inhibitor Landscape for Recurrent Ovarian Cancer TherapySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.